ZofiaPiotrowskaMD

Oncology • Boston, MA

Clinical Instructor in Medicine, Brigham and Women's Hospital

Join to view full profile

Dr. Piotrowska is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Piotrowska's full profile

Already have an account?

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-724-4000

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2016
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Yale School of MedicineClass of 2008

Certifications & Licensure

MA State Medical License 2010 - 2025

Clinical Trials

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer Start of enrollment: 2016 Jun 01
Terminated
Phase 2
A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Start of enrollment: 2017 Oct 31
Active, not recruiting
Phase 2
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Start of enrollment: 2018 Jan 31
Active, not recruiting
Phase 2
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer Start of enrollment: 2019 Jun 06
Recruiting
Phase 1
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer Start of enrollment: 2019 Oct 31
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kina...
Florence K Keane, Beow Y Yeap, Melin J Khandekar, Jessica J Lin, Ibiayi Dagogo-Jack
International Journal of Radiation Oncology, Biology, Physics. 2024-11-20
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.
Daniel Morgensztern, Neal Ready, Melissa L Johnson, Afshin Dowlati, Noura Choudhury
Clinical Cancer Research. 2024-11-15
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.
Ibiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, Justin F Gainor, Jessica J Lin
Lung Cancer. 2024-11-01

Journal Articles

Oxford University Press Has Registered This DOI Pre-Publication
R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Lecia V Sequist, Zofia Piotrowska, Clinical Cancer Research

Lectures

Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).
2019 ASCO Annual Meeting - 6/1/2019
Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Medical Mysteries: She Went Undiagnosed Until Almost Too LateMay 25th, 2024
Highlights at ASCO22: Advancements in NSCLC TherapiesJune 24th, 2022
Therapeutic Advances for Metastatic NSCLC with EGFR Exon 20 Insertion MutationsJuly 1st, 2021
Join now to see all

Other Languages

French, Polish